A detailed history of Efg Asset Management (North America) Corp. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 27,511 shares of NBIX stock, worth $3.45 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
27,511
Previous 33,100 16.89%
Holding current value
$3.45 Million
Previous $4.56 Million 30.49%
% of portfolio
0.54%
Previous 0.8%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$114.58 - $153.15 $640,387 - $855,955
-5,589 Reduced 16.89%
27,511 $3.17 Million
Q2 2024

Jul 25, 2024

SELL
$130.86 - $143.19 $361,697 - $395,777
-2,764 Reduced 7.71%
33,100 $4.56 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $83,064 - $91,562
-637 Reduced 1.75%
35,864 $4.95 Million
Q4 2023

Feb 08, 2024

SELL
$106.07 - $132.76 $172,575 - $216,000
-1,627 Reduced 4.27%
36,501 $4.81 Million
Q3 2023

Nov 02, 2023

BUY
$94.02 - $117.1 $36,667 - $45,669
390 Added 1.03%
38,128 $4.29 Million
Q2 2023

Jul 28, 2023

BUY
$89.53 - $104.87 $335,110 - $392,528
3,743 Added 11.01%
37,738 $3.56 Million
Q1 2023

Apr 27, 2023

BUY
$94.11 - $123.02 $420,201 - $549,284
4,465 Added 15.12%
33,995 $3.44 Million
Q4 2022

Feb 03, 2023

SELL
$106.72 - $127.06 $121,554 - $144,721
-1,139 Reduced 3.71%
29,530 $3.53 Million
Q3 2022

Oct 28, 2022

SELL
$92.03 - $107.81 $247,744 - $290,224
-2,692 Reduced 8.07%
30,669 $3.26 Million
Q2 2022

Aug 04, 2022

BUY
$75.79 - $100.07 $172,649 - $227,959
2,278 Added 7.33%
33,361 $3.25 Million
Q1 2022

Apr 26, 2022

BUY
$72.45 - $94.81 $2.25 Million - $2.95 Million
31,083 New
31,083 $2.92 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.